News | March 12, 2022
Terran Biosciences acquires Concert’s CNS therapeutics portfolio
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Using Orion, pharmaceutical and biotechnology companies, as well as any industrial researcher who wishes to perform electronic structure calculations, can gain access to elastic and flexible computational resources in the Cloud
Laxxon Medical has developed a 3D screen printing technology for the manufacture of structured tablets that enables the controlled release of active pharmaceutical ingredients over time
Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
Subscribe To Our Newsletter & Stay Updated
